Dose-dependent effects of intracoronary verapamil on systemic and coronary hemodynamics

Olaf Oldenburg, Holger Eggebrecht, Joerg Herrmann, Christoph K. Naber, Michael Haude, Raimund Erbel, Dietrich Baumgart

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Calcium antagonists are used in interventional cardiology to prevent coronary vasoconstriction or to overcome the no-reflow phenomenon. The aim of the current study was to evaluate the dose-dependent effects of intracoronary verapamil on systemic and coronary hemodynamics. In 20 patients scheduled for routine coronary angiography, heart rate, blood pressure, and ECG recordings were recorded continuously and intracoronary flow velocity was obtained by intracoronary Doppler measurements in angiographically normal vessels. The cross-sectional area, measured by quantitative coronary angiography, allowed the calculation of coronary blood flow (CBF) and the coronary vascular resistance index (CVRI). Without premedication, increasing dosages of verapamil (0.01 mg, 0.1 mg, 1.0 mg, and 2.0 mg) were injected into the left coronary artery. Intracoronary verapamil administration led to a decrease in systemic blood pressure only after administration of 1.0 mg or 2.0 mg (change in mean arterial pressure: from 87.6 ± 14.6 mmHg to 80.1 ± 14.9 mmHg and 78.5 ± 13.9 mmHg, respectively; both P < 0.05) without a change in heart rate. Epicardial diameters of the left coronary artery increased only at dosages of 1.0 mg and 2.0 mg (from 2.14 ± 0.4 mm to 2.22 ± 0.3 mm, P < 0.01), whereas the coronary blood flow velocity increased significantly at the smallest dosage of 0.01 mg (from 19.9 ± 8.7 cm/s to 33.2 ± 14.9 cm/s, P < 0.001) and was further enhanced with increasing dosages. CBF increased and CVRI decreased at every dosage of verapamil compared with baseline values. CBF increased also after 0.1 mg (from 13.5 ± 6.5 mL/min to 19.5 ± 9.3 mL/min; P < 0.05), reaching a maximal effect after administration of 1.0 mg verapamil (26.3 ±16.1 mL/min, P < 0.05). Application of 2.0 mg did not further increase CBF compared with 1.0 mg. Intracoronary application of verapamil leads to a decrease in systemic blood pressure at higher dosages, whereas heart rate remains unchanged at any dosage. The maximal increase in coronary blood flow and decrease in vascular resistance can be reached by administration of 1.0 mg verapamil into the left coronary artery.

Original languageEnglish (US)
Pages (from-to)651-655
Number of pages5
JournalCardiovascular Drugs and Therapy
Volume14
Issue number6
DOIs
StatePublished - Jan 1 2000
Externally publishedYes

Fingerprint

Verapamil
Hemodynamics
Vascular Resistance
Coronary Vessels
Heart Rate
Coronary Angiography
No-Reflow Phenomenon
Blood Pressure
Blood Flow Velocity
Premedication
Vasoconstriction
Cardiology
Arterial Pressure
Electrocardiography
Hypertension
Calcium

Keywords

  • Blood pressure
  • Calcium antagonists
  • Coronary blood flow
  • Coronary vascular resistance
  • Heart rate
  • Hemodymanic effects
  • Verapamil

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Cite this

Dose-dependent effects of intracoronary verapamil on systemic and coronary hemodynamics. / Oldenburg, Olaf; Eggebrecht, Holger; Herrmann, Joerg; Naber, Christoph K.; Haude, Michael; Erbel, Raimund; Baumgart, Dietrich.

In: Cardiovascular Drugs and Therapy, Vol. 14, No. 6, 01.01.2000, p. 651-655.

Research output: Contribution to journalArticle

Oldenburg, O, Eggebrecht, H, Herrmann, J, Naber, CK, Haude, M, Erbel, R & Baumgart, D 2000, 'Dose-dependent effects of intracoronary verapamil on systemic and coronary hemodynamics', Cardiovascular Drugs and Therapy, vol. 14, no. 6, pp. 651-655. https://doi.org/10.1023/A:1007823116491
Oldenburg, Olaf ; Eggebrecht, Holger ; Herrmann, Joerg ; Naber, Christoph K. ; Haude, Michael ; Erbel, Raimund ; Baumgart, Dietrich. / Dose-dependent effects of intracoronary verapamil on systemic and coronary hemodynamics. In: Cardiovascular Drugs and Therapy. 2000 ; Vol. 14, No. 6. pp. 651-655.
@article{b5d13a6f21d94d34a39bf4bf308c375b,
title = "Dose-dependent effects of intracoronary verapamil on systemic and coronary hemodynamics",
abstract = "Calcium antagonists are used in interventional cardiology to prevent coronary vasoconstriction or to overcome the no-reflow phenomenon. The aim of the current study was to evaluate the dose-dependent effects of intracoronary verapamil on systemic and coronary hemodynamics. In 20 patients scheduled for routine coronary angiography, heart rate, blood pressure, and ECG recordings were recorded continuously and intracoronary flow velocity was obtained by intracoronary Doppler measurements in angiographically normal vessels. The cross-sectional area, measured by quantitative coronary angiography, allowed the calculation of coronary blood flow (CBF) and the coronary vascular resistance index (CVRI). Without premedication, increasing dosages of verapamil (0.01 mg, 0.1 mg, 1.0 mg, and 2.0 mg) were injected into the left coronary artery. Intracoronary verapamil administration led to a decrease in systemic blood pressure only after administration of 1.0 mg or 2.0 mg (change in mean arterial pressure: from 87.6 ± 14.6 mmHg to 80.1 ± 14.9 mmHg and 78.5 ± 13.9 mmHg, respectively; both P < 0.05) without a change in heart rate. Epicardial diameters of the left coronary artery increased only at dosages of 1.0 mg and 2.0 mg (from 2.14 ± 0.4 mm to 2.22 ± 0.3 mm, P < 0.01), whereas the coronary blood flow velocity increased significantly at the smallest dosage of 0.01 mg (from 19.9 ± 8.7 cm/s to 33.2 ± 14.9 cm/s, P < 0.001) and was further enhanced with increasing dosages. CBF increased and CVRI decreased at every dosage of verapamil compared with baseline values. CBF increased also after 0.1 mg (from 13.5 ± 6.5 mL/min to 19.5 ± 9.3 mL/min; P < 0.05), reaching a maximal effect after administration of 1.0 mg verapamil (26.3 ±16.1 mL/min, P < 0.05). Application of 2.0 mg did not further increase CBF compared with 1.0 mg. Intracoronary application of verapamil leads to a decrease in systemic blood pressure at higher dosages, whereas heart rate remains unchanged at any dosage. The maximal increase in coronary blood flow and decrease in vascular resistance can be reached by administration of 1.0 mg verapamil into the left coronary artery.",
keywords = "Blood pressure, Calcium antagonists, Coronary blood flow, Coronary vascular resistance, Heart rate, Hemodymanic effects, Verapamil",
author = "Olaf Oldenburg and Holger Eggebrecht and Joerg Herrmann and Naber, {Christoph K.} and Michael Haude and Raimund Erbel and Dietrich Baumgart",
year = "2000",
month = "1",
day = "1",
doi = "10.1023/A:1007823116491",
language = "English (US)",
volume = "14",
pages = "651--655",
journal = "Cardiovascular Drugs and Therapy",
issn = "0920-3206",
publisher = "Kluwer Academic Publishers",
number = "6",

}

TY - JOUR

T1 - Dose-dependent effects of intracoronary verapamil on systemic and coronary hemodynamics

AU - Oldenburg, Olaf

AU - Eggebrecht, Holger

AU - Herrmann, Joerg

AU - Naber, Christoph K.

AU - Haude, Michael

AU - Erbel, Raimund

AU - Baumgart, Dietrich

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Calcium antagonists are used in interventional cardiology to prevent coronary vasoconstriction or to overcome the no-reflow phenomenon. The aim of the current study was to evaluate the dose-dependent effects of intracoronary verapamil on systemic and coronary hemodynamics. In 20 patients scheduled for routine coronary angiography, heart rate, blood pressure, and ECG recordings were recorded continuously and intracoronary flow velocity was obtained by intracoronary Doppler measurements in angiographically normal vessels. The cross-sectional area, measured by quantitative coronary angiography, allowed the calculation of coronary blood flow (CBF) and the coronary vascular resistance index (CVRI). Without premedication, increasing dosages of verapamil (0.01 mg, 0.1 mg, 1.0 mg, and 2.0 mg) were injected into the left coronary artery. Intracoronary verapamil administration led to a decrease in systemic blood pressure only after administration of 1.0 mg or 2.0 mg (change in mean arterial pressure: from 87.6 ± 14.6 mmHg to 80.1 ± 14.9 mmHg and 78.5 ± 13.9 mmHg, respectively; both P < 0.05) without a change in heart rate. Epicardial diameters of the left coronary artery increased only at dosages of 1.0 mg and 2.0 mg (from 2.14 ± 0.4 mm to 2.22 ± 0.3 mm, P < 0.01), whereas the coronary blood flow velocity increased significantly at the smallest dosage of 0.01 mg (from 19.9 ± 8.7 cm/s to 33.2 ± 14.9 cm/s, P < 0.001) and was further enhanced with increasing dosages. CBF increased and CVRI decreased at every dosage of verapamil compared with baseline values. CBF increased also after 0.1 mg (from 13.5 ± 6.5 mL/min to 19.5 ± 9.3 mL/min; P < 0.05), reaching a maximal effect after administration of 1.0 mg verapamil (26.3 ±16.1 mL/min, P < 0.05). Application of 2.0 mg did not further increase CBF compared with 1.0 mg. Intracoronary application of verapamil leads to a decrease in systemic blood pressure at higher dosages, whereas heart rate remains unchanged at any dosage. The maximal increase in coronary blood flow and decrease in vascular resistance can be reached by administration of 1.0 mg verapamil into the left coronary artery.

AB - Calcium antagonists are used in interventional cardiology to prevent coronary vasoconstriction or to overcome the no-reflow phenomenon. The aim of the current study was to evaluate the dose-dependent effects of intracoronary verapamil on systemic and coronary hemodynamics. In 20 patients scheduled for routine coronary angiography, heart rate, blood pressure, and ECG recordings were recorded continuously and intracoronary flow velocity was obtained by intracoronary Doppler measurements in angiographically normal vessels. The cross-sectional area, measured by quantitative coronary angiography, allowed the calculation of coronary blood flow (CBF) and the coronary vascular resistance index (CVRI). Without premedication, increasing dosages of verapamil (0.01 mg, 0.1 mg, 1.0 mg, and 2.0 mg) were injected into the left coronary artery. Intracoronary verapamil administration led to a decrease in systemic blood pressure only after administration of 1.0 mg or 2.0 mg (change in mean arterial pressure: from 87.6 ± 14.6 mmHg to 80.1 ± 14.9 mmHg and 78.5 ± 13.9 mmHg, respectively; both P < 0.05) without a change in heart rate. Epicardial diameters of the left coronary artery increased only at dosages of 1.0 mg and 2.0 mg (from 2.14 ± 0.4 mm to 2.22 ± 0.3 mm, P < 0.01), whereas the coronary blood flow velocity increased significantly at the smallest dosage of 0.01 mg (from 19.9 ± 8.7 cm/s to 33.2 ± 14.9 cm/s, P < 0.001) and was further enhanced with increasing dosages. CBF increased and CVRI decreased at every dosage of verapamil compared with baseline values. CBF increased also after 0.1 mg (from 13.5 ± 6.5 mL/min to 19.5 ± 9.3 mL/min; P < 0.05), reaching a maximal effect after administration of 1.0 mg verapamil (26.3 ±16.1 mL/min, P < 0.05). Application of 2.0 mg did not further increase CBF compared with 1.0 mg. Intracoronary application of verapamil leads to a decrease in systemic blood pressure at higher dosages, whereas heart rate remains unchanged at any dosage. The maximal increase in coronary blood flow and decrease in vascular resistance can be reached by administration of 1.0 mg verapamil into the left coronary artery.

KW - Blood pressure

KW - Calcium antagonists

KW - Coronary blood flow

KW - Coronary vascular resistance

KW - Heart rate

KW - Hemodymanic effects

KW - Verapamil

UR - http://www.scopus.com/inward/record.url?scp=0034469018&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034469018&partnerID=8YFLogxK

U2 - 10.1023/A:1007823116491

DO - 10.1023/A:1007823116491

M3 - Article

VL - 14

SP - 651

EP - 655

JO - Cardiovascular Drugs and Therapy

JF - Cardiovascular Drugs and Therapy

SN - 0920-3206

IS - 6

ER -